Jeffrey W. Church joined Alba in April, 2007 as Chief Financial Officer.   Prior to joining Alba, Mr. Church held senior financial executive positions with several private and public clinical stage biotech and medical device companies. From 2006 to April 2007, Mr. Church was Vice President, CFO, Treasurer and Corporate Secretary of Novavax, Inc., an early stage vaccine development company.  From 1998 to 2006, Mr. Church served as CFO, Treasurer and Corporate Secretary for GenVec, Inc., a clinical-stage gene therapy company. While at GenVec, he raised over $150 million in equity, debt and facilities financing, including a successful IPO in December 2000. Prior to GenVec, Mr. Church was Executive Vice President, CFO and Director of Biospherics, Inc. (now Spherix), where he directed a team of 250 professionals in sales and marketing, technical services and financial operations. From 1986 to 1996, Mr. Church served as Senior Vice President of Finance and CFO for Meridian Medical Technologies, Inc., where he helped transform Meridian from an unprofitable defense contractor to a profitable medical device company. Meridian was subsequently acquired by King Pharmaceutical for $250 million. Mr. Church started his career in 1979 with the international public accounting firm, Price Waterhouse, advancing to the level of Audit Manager.
 
Mr. Church holds a B.S. degree, summa cum laude, from the University of Maryland and received his Maryland Certified Public Accountant accreditation in 1979.